抗凝治疗在肺心病治疗中的应用观察  

Observation on application of anticoagulant therapy in treatment of pulmonary heart disease

作　　者：湛智杰 ZHAN Zhijie(Gaozhou Hospital of Traditional Chinese Medicine,Guangdong,Gaozhou 525200,China)

机构地区：[1]广东省高州市中医院

出　　处：《中国医药科学》2019年第23期282-285,共4页China Medicine And Pharmacy

摘　　要：目的研究抗凝治疗运用于肺心病中的价值。方法选取我院2018年1~10月纳入的78例肺心病患者作为研究对象,按照随机数字表法分为两组,各39例,研究组采取抗凝治疗,对照组采取常规治疗,对比两组治疗结果。结果研究组总有效率为92.31%,明显高于对照组79.49%(P <0.05)。研究组咳嗽、咳痰、气急、心悸、呼吸困难消退时间及治疗时间均短于对照组(P <0.05)。治疗后研究组的全血高切黏度、全血低切黏度、血浆黏度、红细胞比容及红细胞聚集指数均优于对照组(P <0.05)。治疗后研究组的纤维蛋白原、凝血酶原、血小板膜蛋白-140、氧分压及二氧化碳分压水平均优于对照组(P <0.05)。结论抗凝治疗运用于肺心病中效果显著,可有效缩短治疗时间,促进相关症状消退,改善血液流变学、血气及凝血指标,迅速改善病情。Objective To study the value of anticoagulant therapy in treatment of patients with pulmonary heart disease. Methods 78 patients with pulmonary heart disease who were treated in our hospital from January to October 2018 were selected as research objects. They were randomly divided into two groups, with 39 cases in each group. The study group was given anticoagulant therapy while the control group was given the routine therapy. The curative effects were compared between two groups. Results The total effective rate in the study group(92.31%) was higher than that in the control group(79.49%)(P < 0.05). The disappearance time of cough, expectoration, puffing, palpitation and dyspnea and treatment time in the study group were all shorter than those in the control group(P< 0.05). After treatment, the whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, hematocrit and erythrocyte aggregation index in the study group were better than those in the control group(P < 0.05). After treatment, the levels of fibrinogen, prothrombin, blood platelet membrane protein-140, oxygen partial pressure and partial pressure of carbon dioxide in the study group were better than those in the control group(P < 0.05). Conclusion The anticoagulant therapy for patients with pulmonary heart disease has significant curative effects. It can efficiently shorten the treatment time, promote the resolution of related symptoms, improve the hemorheology, blood gas and coagulation indexes and rapidly improve the illness state of patients.

关 键 词：二氧化碳分压 抗凝治疗 肺心病 血浆粘度 凝血酶原 血小板膜蛋白 

分 类 号：R541.5[医药卫生—心血管疾病]